Jane Street Group LLC Reduces Stock Holdings in AtriCure, Inc. (NASDAQ:ATRC)

Jane Street Group LLC lessened its position in shares of AtriCure, Inc. (NASDAQ:ATRC) by 74.9% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 22,390 shares of the medical device company’s stock after selling 66,943 shares during the quarter. Jane Street Group LLC’s holdings in AtriCure were worth $628,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in ATRC. Arcadia Investment Management Corp MI acquired a new position in shares of AtriCure in the 3rd quarter valued at about $28,000. nVerses Capital LLC lifted its holdings in shares of AtriCure by 733.3% in the 3rd quarter. nVerses Capital LLC now owns 5,000 shares of the medical device company’s stock valued at $140,000 after buying an additional 4,400 shares during the period. Quest Partners LLC lifted its holdings in shares of AtriCure by 38.3% in the 2nd quarter. Quest Partners LLC now owns 5,868 shares of the medical device company’s stock valued at $134,000 after buying an additional 1,626 shares during the period. Captrust Financial Advisors acquired a new position in shares of AtriCure in the 3rd quarter valued at about $230,000. Finally, Mount Yale Investment Advisors LLC lifted its holdings in shares of AtriCure by 32.1% in the 2nd quarter. Mount Yale Investment Advisors LLC now owns 9,743 shares of the medical device company’s stock valued at $222,000 after buying an additional 2,368 shares during the period. Hedge funds and other institutional investors own 99.11% of the company’s stock.

AtriCure Price Performance

Shares of AtriCure stock opened at $32.03 on Friday. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.62 and a quick ratio of 2.59. The business has a 50 day simple moving average of $33.71 and a two-hundred day simple moving average of $28.09. The stock has a market capitalization of $1.56 billion, a P/E ratio of -38.59 and a beta of 1.42. AtriCure, Inc. has a 12 month low of $18.94 and a 12 month high of $39.04.

AtriCure (NASDAQ:ATRC) last posted its quarterly earnings results on Tuesday, October 29th. The medical device company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.02. The business had revenue of $115.91 million during the quarter, compared to analyst estimates of $112.23 million. AtriCure had a negative return on equity of 8.12% and a negative net margin of 8.70%. The business’s revenue was up 17.9% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.20) earnings per share. As a group, analysts predict that AtriCure, Inc. will post -0.72 EPS for the current fiscal year.

Analyst Ratings Changes

ATRC has been the subject of several analyst reports. StockNews.com raised AtriCure from a “sell” rating to a “hold” rating in a report on Saturday, September 14th. Oppenheimer boosted their price objective on AtriCure from $32.00 to $36.00 and gave the company an “outperform” rating in a report on Wednesday, October 30th. JPMorgan Chase & Co. reissued an “overweight” rating and issued a $40.00 price objective on shares of AtriCure in a report on Tuesday, December 17th. UBS Group upped their price target on AtriCure from $35.00 to $40.00 and gave the stock a “buy” rating in a report on Wednesday, October 30th. Finally, Needham & Company LLC upped their price target on AtriCure from $34.00 to $40.00 and gave the stock a “buy” rating in a report on Wednesday, October 30th. One analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $42.00.

AtriCure Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.